Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report) dropped 5.2% during trading on Tuesday . The company traded as low as $13.77 and last traded at $13.78. Approximately 338,491 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 519,221 shares. The stock had previously closed at $14.53.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on GENB shares. Wall Street Zen cut Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Morgan Stanley raised their target price on Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Cantor Fitzgerald started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating on the stock. Zacks Research raised Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Finally, Guggenheim began coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $30.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.40.
Check Out Our Latest Analysis on Generate Biomedicines
Generate Biomedicines Price Performance
Generate Biomedicines (NASDAQ:GENB – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).
Generate Biomedicines Company Profile
Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.
Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.
Featured Articles
- Five stocks we like better than Generate Biomedicines
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.
